A novel Chk1-binding peptide that enhances genotoxic sensitivity through the cellular redistribution of nuclear Chk1

Kim,Kwang  Seok; Choi,Kyu  Jin; Bae,Sangwoo

doi:10.3892/ijmm.2016.2762

A novel Chk1-binding peptide that enhances genotoxic sensitivity through the cellular redistribution of nuclear Chk1

Authors:
- Kwang Seok Kim
- Kyu Jin Choi
- Sangwoo Bae
View Affiliations

Affiliations: Division of Radiation Effects, Korea Institute of Radiological and Medical Sciences, Seoul 139-706, Republic of Korea
Published online on: September 30, 2016 https://doi.org/10.3892/ijmm.2016.2762
Pages: 1490-1498
Copyright: © Kim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Since checkpoint kinase 1 (Chk1) is an essential factor for cell viability following DNA damage, the inhibition of Chk1 has been a major focus of pharmaceutical development to enhance the sensitivity of tumor cells to chemo- and radiotherapy that damage DNA. However, due to the off-target effects of conventional Chk1-targeting strategies and the toxicity of Chk1 inhibitors, alternative strategies are required to target Chk1. To facilitate such efforts, in this study, we identified a specific Chk1-binding 12-mer peptide from the screening of a phage display library and characterized the peptide in terms of cellular cytotoxicity, and in terms of its effect on Chk1 activity and sensitivity to genotoxic agents. This peptide, named N-terminal Chk1-binding peptide (Chk1‑NP), bound the kinase domain of Chk1. Simulation of the binding revealed that the very N-terminus of the Chk1 kinase domain is the potential peptide binding site. Of note, the polyarginine-mediated internalization of Chk1‑NP redistributed nuclear Chk1 with a prominent decrease in the nucleus in the absence of DNA damage. Treatment with Chk1‑NP peptide alone decreased the viability of p53-defective HeLa cells, but not that of p53-functional NCI-H460 cells under normal conditions. The treatment of HeLa or NCI-H460 cells with the peptide significantly enhanced radiation sensitivity following ionizing radiation (IR) with a greater enhancement observed in HeLa cells. Moreover, the IR-induced destabilization of Chk1 was aggravated by treatment with Chk1‑NP. Therefore, the decreased nuclear localization and protein levels of Chk1 seem to be responsible for the enhanced cancer cell killing following combined treatment with IR and Chk1‑NP. The approach using the specific Chk1-binding peptide may facilitate the mechanistic understanding and potential modulation of Chk1 activities and may provide a novel rationale for the development of specific Chk1-targeting agents.

View Figures

View References

1	Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004. View Article : Google Scholar : PubMed/NCBI
2	Ciccia A and Elledge SJ: The DNA damage response: Making it safe to play with knives. Mol Cell. 40:179–204. 2010. View Article : Google Scholar : PubMed/NCBI
3	Smith J, Tho LM, Xu N and Gillespie DA: The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res. 108:73–112. 2010. View Article : Google Scholar : PubMed/NCBI
4	Sørensen CS, Syljuåsen RG, Falck J, Schroeder T, Rönnstrand L, Khanna KK, Zhou BB, Bartek J and Lukas J: Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell. 3:247–258. 2003. View Article : Google Scholar : PubMed/NCBI
5	Falck J, Mailand N, Syljuåsen RG, Bartek J and Lukas J: The ATM-Chk2-Cdc25A checkpoint pathway guards against radio-resistant DNA synthesis. Nature. 410:842–847. 2001. View Article : Google Scholar : PubMed/NCBI
6	Patil M, Pabla N and Dong Z: Checkpoint kinase 1 in DNA damage response and cell cycle regulation. Cell Mol Life Sci. 70:4009–4021. 2013. View Article : Google Scholar : PubMed/NCBI
7	Tapia-Alveal C, Calonge TM and O'Connell MJ: Regulation of chk1. Cell Div. 4:82009. View Article : Google Scholar : PubMed/NCBI
8	Zhang Y and Hunter T: Roles of Chk1 in cell biology and cancer therapy. Int J Cancer. 134:1013–1023. 2014. View Article : Google Scholar
9	Zhang YW, Otterness DM, Chiang GG, Xie W, Liu YC, Mercurio F and Abraham RT: Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell. 19:607–618. 2005. View Article : Google Scholar : PubMed/NCBI
10	Leung-Pineda V, Huh J and Piwnica-Worms H: DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and in cells experiencing replication stress. Cancer Res. 69:2630–2637. 2009. View Article : Google Scholar : PubMed/NCBI
11	Zhang YW, Brognard J, Coughlin C, You Z, Dolled-Filhart M, Aslanian A, Manning G, Abraham RT and Hunter T: The F box protein Fbx6 regulates Chk1 stability and cellular sensitivity to replication stress. Mol Cell. 35:442–453. 2009. View Article : Google Scholar : PubMed/NCBI
12	Dent P, Tang Y, Yacoub A, Dai Y, Fisher PB and Grant S: CHK1 inhibitors in combination chemotherapy: Thinking beyond the cell cycle. Mol Interv. 11:133–140. 2011. View Article : Google Scholar : PubMed/NCBI
13	Merry C, Fu K, Wang J, Yeh IJ and Zhang Y: Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle. 9:279–283. 2010. View Article : Google Scholar
14	Suganuma M, Kawabe T, Hori H, Funabiki T and Okamoto T: Sensitization of cancer cells to DNA damage-induced cell death by specific cell cycle G2 checkpoint abrogation. Cancer Res. 59:5887–5891. 1999.PubMed/NCBI
15	Kawabe T: G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther. 3:513–519. 2004.PubMed/NCBI
16	Zhao H, Watkins JL and Piwnica-Worms H: Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA. 99:14795–14800. 2002. View Article : Google Scholar : PubMed/NCBI
17	Kim KS, Heo JI, Choi KJ and Bae S: Enhancement of cellular radiation sensitivity through degradation of Chk1 by the XIAP-XAF1 complex. Cancer Biol Ther. 15:1622–1634. 2014. View Article : Google Scholar : PubMed/NCBI
18	Saladin A, Rey J, Thévenet P, Zacharias M, Moroy G and Tufféry P: PEP-SiteFinder: a tool for the blind identification of peptide binding sites on protein surfaces. Nucleic Acids Res. 42:W221–W226. 2014. View Article : Google Scholar : PubMed/NCBI
19	Chen P, Luo C, Deng Y, Ryan K, Register J, Margosiak S, Tempczyk-Russell A, Nguyen B, Myers P, Lundgren K, et al: The 1.7 A crystal structure of human cell cycle checkpoint kinase Chk1: Implications for Chk1 regulation. Cell. 100:681–692. 2000. View Article : Google Scholar : PubMed/NCBI
20	Zhao B, Bower MJ, McDevitt PJ, Zhao H, Davis ST, Johanson KO, Green SM, Concha NO and Zhou BB: Structural basis for Chk1 inhibition by UCN-01. J Biol Chem. 277:46609–46615. 2002. View Article : Google Scholar : PubMed/NCBI
21	Fuchs SM and Raines RT: Pathway for polyarginine entry into mammalian cells. Biochemistry. 43:2438–2444. 2004. View Article : Google Scholar : PubMed/NCBI
22	Wang J, Han X, Feng X, Wang Z and Zhang Y: Coupling cellular localization and function of checkpoint kinase 1 (Chk1) in checkpoints and cell viability. J Biol Chem. 287:25501–25509. 2012. View Article : Google Scholar : PubMed/NCBI
23	Dunleavy EM, Roche D, Tagami H, Lacoste N, Ray-Gallet D, Nakamura Y, Daigo Y, Nakatani Y and Almouzni-Pettinotti G: HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell. 137:485–497. 2009. View Article : Google Scholar : PubMed/NCBI
24	Sidi S, Sanda T, Kennedy RD, Hagen AT, Jette CA, Hoffmans R, Pascual J, Imamura S, Kishi S, Amatruda JF, et al: Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, Bcl-2, and caspase-3. Cell. 133:864–877. 2008. View Article : Google Scholar : PubMed/NCBI
25	Parsels LA, Qian Y, Tanska DM, Gross M, Zhao L, Hassan MC, Arumugarajah S, Parsels JD, Hylander-Gans L, Simeone DM, et al: Assessment of chk1 phosphorylation as a pharmaco-dynamic biomarker of chk1 inhibition. Clin Cancer Res. 17:3706–3715. 2011. View Article : Google Scholar : PubMed/NCBI
26	Katsuragi Y and Sagata N: Regulation of Chk1 kinase by auto-inhibition and ATR-mediated phosphorylation. Mol Biol Cell. 15:1680–1689. 2004. View Article : Google Scholar : PubMed/NCBI
27	Scorah J, Dong MQ, Yates JR III, Scott M, Gillespie D and McGowan CH: A conserved proliferating cell nuclear antigen-interacting protein sequence in Chk1 is required for checkpoint function. J Biol Chem. 283:17250–17259. 2008. View Article : Google Scholar : PubMed/NCBI
28	Smits VA, Reaper PM and Jackson SP: Rapid PIKK-dependent release of Chk1 from chromatin promotes the DNA-damage checkpoint response. Curr Biol. 16:150–159. 2006. View Article : Google Scholar
29	Wang J, Han X and Zhang Y: Autoregulatory mechanisms of phosphorylation of checkpoint kinase 1. Cancer Res. 72:3786–3794. 2012. View Article : Google Scholar : PubMed/NCBI
30	Shimada M, Niida H, Zineldeen DH, Tagami H, Tanaka M, Saito H and Nakanishi M: Chk1 is a histone H3 threonine 11 kinase that regulates DNA damage-induced transcriptional repression. Cell. 132:221–232. 2008. View Article : Google Scholar : PubMed/NCBI
31	Perego P, Gatti L, Righetti SC, Beretta GL, Carenini N, Corna E, Dal Bo L, Tinelli S, Colangelo D, Leone R, et al: Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells. Int J Cancer. 105:617–624. 2003. View Article : Google Scholar : PubMed/NCBI
32	Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
33	Bartucci M, Svensson S, Romania P, Dattilo R, Patrizii M, Signore M, Navarra S, Lotti F, Biffoni M, Pilozzi E, et al: Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death Differ. 19:768–778. 2012. View Article : Google Scholar :
34	Wang X, Ma Z, Xiao Z, Liu H, Dou Z, Feng X and Shi H: Chk1 knockdown confers radiosensitization in prostate cancer stem cells. Oncol Rep. 28:2247–2254. 2012.PubMed/NCBI
35	Koniaras K, Cuddihy AR, Christopoulos H, Hogg A and O'Connell MJ: Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene. 20:7453–7463. 2001. View Article : Google Scholar : PubMed/NCBI
36	Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A, et al: Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest. 122:1541–1552. 2012. View Article : Google Scholar : PubMed/NCBI